UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE TO
(Amendment No. 4)
TENDER OFFER STATEMENT
UNDER SECTION 14(D)(1) OR SECTION 13(E)(1) OF
THE SECURITIES EXCHANGE ACT OF 1934
SOMANETICS CORPORATION
(Name Of Subject Company (Issuer))
UNITED STATES SURGICAL CORPORATION
COVIDIEN DE CORP.
(Names of Filing Persons (Offerors))
Common Shares, par value $0.01 per share
(Title of Class of Securities)
834445405
(CUSIP Number of Common Stock)
John H. Masterson
United States Surgical Corporation
c/o Covidien
15 Hampshire Street
Mansfield, MA 02048
Telephone: (508) 261-8000
(Name, address and telephone number of person authorized
to receive notices and communications on behalf of filing persons)
with copies to:
Joseph L. Johnson III
Goodwin Procter LLP
Exchange Place
Boston, Massachusetts 02109
Telephone: (617) 570-1000
CALCULATION OF FILING FEE
| Transaction Valuation* |
Amount Of Filing Fee** | |
| $343,688,025 | $24,504.96 |
| * | Estimated solely for purposes of calculating amount of filing fee in accordance with Rule 0-11 under the Securities Exchange Act of 1934. The transaction value is based upon the offer to purchase 13,747,521 outstanding Common Shares of Somanetics Corporation at a purchase price of $25.00 cash per share. Such number of outstanding Common Shares represents the total of 11,953,384 issued and outstanding Common Shares outstanding options with respect to 1,794,137 Common Shares, in each case as of June 16, 2010. |
| ** | The amount of filing fee is calculated in accordance with Rule 0-11 of the Securities Exchange Act of 1934, as amended, and Fee Rate Advisory No. 4 for fiscal year 2010 issued by the Securities and Exchange Commission. Such fee equals .00713% of the transaction value. |
| x | Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number or the Form or Schedule and the date of its filing. |
| Amount Previously Paid: |
$ 24,504.96 | |
| Form or Registration No.: |
Schedule TO-T | |
| Filing Party: |
United States Surgical Corporation | |
| Date Filed: |
June 25, 2010 | |
| ¨ | Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. |
Check the appropriate boxes below to designate any transactions to which the statement relates:
| x | third-party tender offer subject to Rule 14d-1. |
| ¨ | issuer tender offer subject to Rule 13e-4. |
| ¨ | going-private transaction subject to Rule 13e-3. |
| ¨ | amendment to Schedule 13D under Rule 13d-2. |
Check the following box if the filing is a final amendment reporting the results of the tender offer: ¨
This Amendment No. 4 to the Tender Offer Statement on Schedule TO (this “Amendment”), filed with the Securities and Exchange Commission on July 21, 2010, amends and supplements the Tender Offer Statement on Schedule TO filed on June 25, 2010 (the “Schedule TO”) and relates to a tender offer by Covidien DE Corp., a Delaware corporation (the “Offeror”) and a wholly owned subsidiary of United States Surgical Corporation, a Delaware corporation (“Parent”), to purchase all of the outstanding Common Shares, par value $0.01 per share (the “Shares”), of Somanetics Corporation, a Michigan corporation (the “Company”), at a purchase price of $25.00 per Share, net to the seller in cash, without interest thereon, less any applicable withholding taxes, and subject to the conditions set forth in the Offer to Purchase for Cash dated June 25, 2010 (the “Offer to Purchase”) and in the related Letter of Transmittal (the “Letter of Transmittal” which, together with the Offer to Purchase, as each may be amended and supplemented from time to time, constitute the “Offer”). This Amendment is being filed on behalf of the Offeror and Parent.
The information set forth in the Offer to Purchase and the Letter of Transmittal, copies of which are filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively, is incorporated by reference in answers to Items 1 through 9 and Item 11 of the Schedule TO, and is supplemented by the information specifically provided herein.
| ITEM | 11. ADDITIONAL INFORMATION |
Item 11 of the Schedule TO is hereby amended and supplemented by replacing the first paragraph added to that Item in Amendment No. 1 and the first paragraph added to that Item in Amendment No. 3 with the following text:
“On June 30, 2010, a plaintiff filed a purported shareholder class action complaint in the Sixth Judicial Circuit Court for the State of Michigan, Oakland County (the “Michigan Action”). The complaint, captioned Stanley Manne v. Somanetics Corporation, et al., names as defendants the Company and the members of the Company’s board of directors, as well as Parent, the Offeror and Covidien plc. The plaintiff claims that the Company’s directors breached their fiduciary duties to the Company’s shareholders. The plaintiff further claims that Parent, the Offeror and Covidien plc have aided and abetted the purported breach of fiduciary duties. In support of the plaintiff’s claims, the complaint alleges that the proposed transaction between the Company, Parent and the Offeror involves inadequate disclosure and inadequate consideration. The complaint seeks injunctive relief, the imposition of a constructive trust in favor of plaintiff and the awarding of attorneys’ and experts’ fees.
On July 15, 2010, a plaintiff filed a purported shareholder class action complaint in the United States District Court, Eastern District of Michigan (the “Federal Action”). The complaint, captioned Maryellen Farrelly v. Bruce Barrett, et al., names as defendants the Company and the members of the Company’s board of directors, as well as Parent and the Offeror. The plaintiff claims that the Company’s directors breached their fiduciary duties to the Company’s shareholders. The plaintiff further claims that Parent, the Offeror and the Company have aided and abetted the purported breach of fiduciary duties. In support of the plaintiff’s claims, the complaint alleges that the proposed transaction between the Company, Parent and the Offeror involves inadequate disclosure and inadequate consideration. The complaint seeks injunctive relief and the awarding of attorneys’ and experts’ fees.
While the defendants believe that both the Michigan Action and the Federal Action (together, the “Court Actions”) are entirely without merit and that they have valid defenses to all claims, in an effort to minimize cost and expense of litigation arising in connection with the Court Actions, on July 21, 2010, the parties to the Court Actions reached an agreement in principle to settle all claims asserted therein. In connection with this agreement, the Company agreed to amend the Schedule 14D-9, previously filed with the SEC, to include certain supplemental disclosures, in addition to certain other terms to be agreed upon by the parties. The settlement is subject to, among other things, confirmatory discovery, the execution of one or more stipulations of settlement and court approval. Subject to further definitive documentation and upon court approval, the defendants will be released by the plaintiffs and all members of the relevant class of Company shareholders from all claims arising out of the Offer, the Merger and the transactions contemplated by the Merger Agreement. The settlement, including the payment by the Company or any successor thereto of attorneys’ fees, is also contingent upon, among other things, the Merger becoming effective under applicable law. In the event that the settlement is not approved and such conditions are not satisfied, the defendants will continue to vigorously defend both the Court Actions.”
2
SIGNATURES
After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
UNITED STATES SURGICAL CORPORATION
Dated: July 21, 2010
By: /s/ Matthew J. Nicolella
Name: Matthew J. Nicolella
Title: Vice President and Assistant Secretary
COVIDIEN DE CORP.
Dated: July 21, 2010
By: /s/ Matthew J. Nicolella
Name: Matthew J. Nicolella
Title: Vice President and Assistant Secretary
3
EXHIBIT INDEX
| (a)(1)(A) | Offer to Purchase for Cash, dated June 25, 2010.* | |
| (a)(1)(B) | Form of Letter of Transmittal.* | |
| (a)(1)(C) | Form of Notice of Guaranteed Delivery.* | |
| (a)(1)(D) | Form of Letter to Brokers, Dealers, Banks, Trust Companies and Other Nominees.* | |
| (a)(1)(E) | Form of Letter to Clients for Use by Brokers, Dealers, Banks, Trust Companies and Other Nominees.* | |
| (a)(2) | None. | |
| (a)(3) | None. | |
| (a)(4) | None. | |
| (a)(5)(A) | Joint Press Release issued by Covidien plc and Somanetics Corporation, dated June 16, 2010 (incorporated herein by reference to Exhibit 99.1 to the Current Report on Form 8-K filed by Covidien plc on June 16, 2010).* | |
| (a)(5)(B) | Summary Advertisement published in the Wall Street Journal on June 25, 2010.* | |
| (a)(5)(C) | Complaint filed by Stanley Manne, individually and on behalf of all others similarly situated, on June 30, 2010, in the Sixth Judicial Circuit Court for the State of Michigan, Oakland County.* | |
| (a)(5)(D) | Complaint filed by Maryellen Farrelly, individually and on behalf of all others similarly situated, on July 15, 2010, in the United States District Court, Eastern District of Michigan.* | |
| (b) | None. | |
| (d)(1) | Agreement and Plan of Merger, dated as of June 16, 2010, by and between United States Surgical Corporation, Covidien DE Corp. and Somanetics Corporation.* | |
| (d)(2) | Tender and Voting Agreement, dated as of June 16, 2010, by and between United States Surgical Corporation, Covidien DE Corp. and Bruce J. Barrett.* | |
| (d)(3) | Confidentiality and Standstill Agreement, dated as of March 16, 2010, by and between United States Surgical Corporation and Somanetics Corporation.* | |
| (d)(4) | Guaranty, dated as of June 16, 2010, by Covidien International Finance S.A.* | |
| (g) | None. | |
| (h) | None. | |
| * | Previously filed |
4